UNSPSC 51151636: Edrophonium chloride

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C10H16NO.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QO611KSM5P, chemically known as benzenaminium, n-ethyl-3-hydroxy-n,n-dimethyl- but generally known as edrophonium chloride, which bears US NIH Compound Identifier 3202. European Medicines Agency schedules Edrophonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06461MIG.

UNSPSC 51151636 Edrophonium chloride is a Commodity code that in recent state and local procurement appears to span a broader range of pharmaceutical products and pharmacy benefit program services than the narrow code name suggests. State and local health agencies are using this code to solicit naloxone, drug deactivation systems, and direct-to-manufacturer prescription fulfillment capabilities. The solicitations reflect public health and cost-management priorities: Seminole County, Florida is procuring naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission is exploring vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. Issuing bodies include county health departments and state HHS agencies, each with distinct operational scopes—county-level procurement focused on tangible pharmaceutical supplies with defined annual volumes, and state-level procurement exploring systemic pharmacy benefit delivery models.

Activity is geographically dispersed across at least Florida and Texas. Seminole County's IFB60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; the contract includes a two-year initial term with a one-year renewal option, requires E-Verify compliance and drug-free workplace certification, and may be FEMA-funded. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, requests vendor information on direct contracting with manufacturers outside existing PBM and GPO relationships, focusing on negotiated net pricing models and value-based agreements. Neither opportunity specifies explicit set-asides for disadvantaged enterprises. The mismatch between the code's nominal scope (a specific diagnostic agent) and the actual work being solicited (broad pharmaceutical procurement and pharmacy benefit program design) suggests this code may be a catch-all for state and local pharmaceutical purchasing, making it a code worth monitoring for volume but unlikely to signal opportunities narrowly aligned with the chemical name alone.